Independent Review of the 68th Annual AASLD

AASLD 17 Comp Review Theme 1 

AASLD17_Comp-Review_STARTVIEWING_V1.1.jpg

About the Program

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 68th American Association for the Study of the Liver Diseases Annual Meeting (AASLD 2017). This program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C presented at AASLD 2017. This review and discussion will provide a comprehensive overview of each of the posters and presentations as selected by our faculty panel. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This activity will enable participating health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.

Back to Top   

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2017 

  • Employ the current treatment paradigms for CHC, including the studies and data presented at AASLD 2017, to improve patient care

  • Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at AASLD 2017 to decide on appropriate planning of therapy for patients with CHC


Release Date:  November 1, 2017

Expiration Date:  November 1, 2018

Estimated time to complete this program: 15-30 minutes per module

Media: Internet

Back to Top

Course Director

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty

Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany 

Back to Top  

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Nezam Afdhal, MD

  • Consulting Fees: Merck, Gilead, Echosens, Ligand, Janssen, Shionogi
  • Employee/Salary: Sprint Bank Pharmaceuticals (Research Company)
  • Other: Director-TRIO Healthcare
  • Stock: Allurion, Spring Bank Pharmaceuticals
  • Stock Options: SpringBank Pharmaceuticals, TRIO

Fred Poordad, MD

  • Consulting Fees: Abbvie, Gilead, Merck, BMS, Salix
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbvie, Gilead, Merck, BMS, Salix
  • Research Support: Abbvie, Gilead, Merck, BMS, Salix

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Gilead, Hexal, Merck, ViiV
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents: Abbott, Gilead, Janssen, Merck
  • Contracted Research: Gilead

Mark Sulkowski, MD

  • Contracted Research (to JHU): Abbvie, Gilead, Merck, Tobira
  • Consulting Fees: Abbvie, CoCrystal, Gilead, Janssen, Merck, Trek
  • Other: Gilead - DSMB Member

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receved CME credit for this activity.  During the period, November 1, 2017 through November 1, 2018 participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 12249.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Poster/Presentation Listing

Abstract_LB-27_button.jpg

Survival Benefit of Direct-Acting Antiviral Therapy in Patients with
Decompensated Cirrhosis

Abstract_1178_button

Current DAAs Including Treatment of DAA Non-Responders and RASs

Abstract_78_button

Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on
Mortality and Hepatocellular Carcinoma

Abstract_64_button.jpg

Significant and Sustained Improvement of Health-Related Quality of Life
Scores in Patients with Hepatitis C and Sustained Virologic Response

Abstract_196_button.jpg

100% SVR with 8 Weeks of Ledipasvir/Sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial

Abstract_1175_button.jpg

C-BREEZE-1, C-BREEZE - 2 and OMEGA-1 Studies

Abstract_1115_button.jpg Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-start Rates and Increased Time to Start Using Real-world Data from the TRIO Network
Abstract_125_button.jpg

The Impact of Hepatitis C Diagnosis on Substance-use Behaviors in Patients Engaged in Opioid Substitution Therapy

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top

 

 

PIM_small

This activity is supported by an independent medical educational grant from Merck & Co.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

 


Prepare to print

Share this page:

Get link code to this page                     


Back to Top